CSBio CSBio

X
[{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR\u2122 Therapy for Relapsed or Refractory T-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Gracell Biotechnologies"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and MD Anderson Enter a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT in Rare Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"orgOrder":0,"company":"BeiGene","sponsor":"Hutchison China MediTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"BeiGene"},{"orgOrder":0,"company":"Yimiao Shenzhou Pharmaceutical","sponsor":"EdiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boya Series and Yimiao China Announced that They will Jointly Develop Allogeneic CAR-T Therapy For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Yimiao Shenzhou Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences and Merck Announce Collaboration to Explore Promising New Composition Treatment for Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soundny Presents a New Drug-based Alternative in Fight Against Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hubei Soundny Biotechnology"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","amount":"$418.0 million","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"I-Mab Biopharma"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"$69.2 million","upfrontCash":"$5.2 million","newsHeadline":"Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wigen Biomedicine Technology"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antengene signs MoU with WuXi Biologics to advance development of innovative oncology medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Antengene"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$40.0 million","newsHeadline":"Fochon Pharmaceuticals Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Fosun Pharmaceutical"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Adagene Suzhou Limited"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xuanzhu Biopharm Acquires Combio Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,407.0 million","upfrontCash":"$47.0 million","newsHeadline":"China\u2019s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland\u2019s Merck Sharp & Dohme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sichuan Kelun Pharmaceutical"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Full-Life Technologies"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ablaze Pharma"}]

Find Novel Oncology Drugs in Clinical Development in CHINA

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal healthy tissue.

            Lead Product(s): Actinium-225

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Yonghe Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Focus-X is developing targeted radiopharmaceuticals-based therapeutic to treat cancer based on its proprietary peptide engineering technology. Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from concept to product.

            Lead Product(s): Radiopharmaceutical Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Focus-X Therapeutics

            Deal Size: $245.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".

            Lead Product(s): Macromolecule-based Therapeutic

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: $1,407.0 million Upfront Cash: $47.0 million

            Deal Type: Licensing Agreement May 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.

            Lead Product(s): KM257

            Therapeutic Area: Oncology Product Name: KM257

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Xuanzhu Biopharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As a result of the collaboration, Adagene discovered antibodies that Dr. Child’s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer in adults, according to Frost & Sullivan.

            Lead Product(s): CAR-T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and Hong Kong.

            Lead Product(s): FCN-338

            Therapeutic Area: Oncology Product Name: FCN-338

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $440.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement October 30, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of first-in-class or best-in-class innovative cancer therapies.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Wigen Biomedicine will transfer its 50% interest in four of its drug candidates, XPO1 inhibitor, Aurora-A inhibitor, EGFR-exon20 inhibitor, and 4th generation EGFR inhibitor. Junshi will be granted the exclusive rights for production and commercialization for these drugs.

            Lead Product(s): WJ1075

            Therapeutic Area: Oncology Product Name: WJ1024

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences

            Deal Size: $69.2 million Upfront Cash: $5.2 million

            Deal Type: Collaboration September 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company will receive all proceeds from the private placement and intends to utilize them to fund the ongoing and planned research and clinical programs globally as well as the development of its commercialization capabilities in China.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Hillhouse Capital Group

            Deal Size: $418.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement September 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The research highlights a Methotrexate-loaded microvesicles tumor therapy for cholangiocarcinoma, approved for clinical use has shown significant efficacy and safety in the treatment of cholangiocarcinoma.

            Lead Product(s): Methotrexate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY